NCT07022145

Brief Summary

There are both common and individual characteristics in patients with type B aortic dissection. Currently, for all subtypes of acute type B dissection, proximal endovascular repair is mostly performed during the subacute phase, while the distal dissection of the descending aorta is often managed with a "watch and wait" strategy. However, such a uniform approach carries potential risks, including imprecise indications, inappropriate timing, and uncertain prognosis. Our research team has previously established a comprehensive database and imaging repository of nearly 10,000 cases of type B dissection. Building upon existing subtypes-such as acute complicated, uncomplicated, penetrating atherosclerotic ulcer, and intramural hematoma-we have further explored refined classifications, including acute high-risk types and localized contrast enhancement of the aortic wall. For patients with different subtypes and at different stages of dissection-such as hyperacute, acute, or subacute-it is critical to develop individualized treatment strategies. These may include optimal medical therapy, isolated proximal endovascular repair, or combined proximal repair with distal bare stent implantation. Therefore, a large-scale clinical study is urgently needed to identify the optimal timing and approach for intervention based on refined classification schemes, and to establish personalized, stratified treatment strategies for different patient groups. This project aims to conduct a real-world, prospective, multicenter, parallel-controlled study to compare outcomes between isolated proximal endovascular repair and combined proximal repair with distal bare stent implantation in patients with acute complicated or high-risk type B aortic dissection. The goal is to determine the most effective surgical approach for improving distal perfusion and promoting favorable aortic remodeling, thereby guiding treatment decision-making.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
438

participants targeted

Target at P75+ for all trials

Timeline
49mo left

Started Jun 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress19%
Jun 2025May 2030

Study Start

First participant enrolled

June 1, 2025

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

June 7, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 15, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2030

Expected
Last Updated

June 15, 2025

Status Verified

June 1, 2025

Enrollment Period

11 months

First QC Date

June 7, 2025

Last Update Submit

June 7, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • 30-day Postoperative Positive Remodeling Rate of the Descending Thoracic Aorta

    (Number of subjects with positive remodeling of the descending thoracic aorta at the 30-day postoperative visit / Total number of subjects who completed the 30-day postoperative visit) × 100%

    30 days

  • 12-month Postoperative Degree of Positive Remodeling of the Descending Thoracic Aorta

    Positive aortic remodeling is defined as meeting at least one of the following criteria: A reduction in the maximum diameter or volume of the false lumen, accompanied by either a decrease or an increase of less than 5 mm in the total aortic diameter or volume; An increase in the maximum diameter or volume of the true lumen, accompanied by either a decrease or an increase of less than 5 mm in the total aortic diameter or volume; A reduction in the maximum aortic diameter (along with changes in the diameters of both the true and false lumens). Formula for calculating the degree of positive remodeling of the descending thoracic aorta at 12 months postoperatively: (Maximum true lumen diameter of the descending thoracic aorta at 12 months post-op / Maximum total lumen diameter at 12 months post-op) - (Preoperative maximum true lumen diameter / Preoperative maximum total lumen diameter of the descending thoracic aorta)

    12 months

Secondary Outcomes (7)

  • 3-month Postoperative Positive Remodeling Rate of the Descending Thoracic Aorta

    3 months

  • Incidence of Distal Stent-Induced New Entry (d-SINE) During Follow-up Incidence of Distal Stent-Induced New Entry (d-SINE) During Follow-up Incidence of Distal Stent-Induced New Entry (d-SINE) During Follow-up

    5 years

  • Rate of Visceral Arterial Branch Lumen Loss During Follow-up

    5 years

  • Degree of Positive Remodeling of the Abdominal Aorta During Follow-up Degree of Positive Remodeling of the Abdominal Aorta During Follow-up Degree of Positive Remodeling of the Abdominal Aorta During Follow-up

    5 years

  • All-Cause Mortality Rate During Follow-up

    5 years

  • +2 more secondary outcomes

Study Arms (2)

PSG

Type B aortic dissection patients treated with proximal stent-graft

Procedure: Endovascular repair

PSG+DBS

Type B aortic dissection patients treated with proximal stent-graft combined with distal bare stent

Procedure: Endovascular repair

Interventions

Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients

PSGPSG+DBS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Study population: Patients with type B aortic dissection receiving real-world clinical diagnosis and treatment at each participating center. Definition of Acute Complicated Type B Aortic Dissection: Patients diagnosed with type B aortic dissection within 14 days of symptom onset who present with rupture/imminent rupture, associated ischemic syndromes (bowel, renal, or lower limb ischemia), radiologic progression of dissection or aortic dilation during hospitalization, uncontrolled hypertension, or refractory pain lasting more than 12 hours. Definition of Acute High-Risk Type B Aortic Dissection: Patients diagnosed with type B aortic dissection within 14 days of symptom onset who exhibit one or more of the following: total aortic diameter \>40 mm, false lumen diameter \>22 mm, primary entry tear \>10 mm, entry tear located on the inner curvature, hemothorax, radiologic signs of ischemia (bowel, renal, or lower limb), or recurrent pain/symptoms.

You may qualify if:

  • Male participants aged ≥18 years or non-pregnant female participants
  • Diagnosed with acute complicated type B aortic dissection (defined as rupture/imminent rupture, associated ischemic syndromes \[bowel, renal, or lower limb ischemia\], radiologic progression of dissection or aortic dilation during hospitalization, uncontrolled hypertension, or refractory pain lasting over 12 hours), or high-risk type B dissection (defined as total aortic diameter \>40 mm, false lumen diameter \>22 mm, primary entry tear \>10 mm, entry on the inner curvature, hemothorax, radiologic signs of ischemia \[bowel, renal, or lower limb\], or recurrent pain/symptoms).
  • Patients deemed suitable for TEVAR or TEVAR combined with supra-aortic single-branch endovascular repair, as assessed by the investigator
  • Patients who understand the purpose of the study, voluntarily agree to participate by signing informed consent, and are willing to comply with follow-up requirements

You may not qualify if:

  • Subjects with hemodynamic instability or ruptured aortic dissection
  • Subjects who, due to anatomical factors, are unsuitable for isolated TEVAR or TEVAR combined with supra-aortic single-branch reconstruction
  • Subjects with connective tissue disorders, such as Marfan syndrome
  • Subjects in poor general condition who cannot tolerate general anesthesia
  • Subjects with known allergies to contrast agents or stent materials such as nitinol
  • Subjects with a life expectancy of less than 12 months
  • Subjects with a history of myocardial infarction or unstable angina within the past 3 months
  • Subjects with a history of TIA or cerebral infarction within the past 3 months
  • Subjects with serum creatinine levels \>2.5 times the upper limit of normal or currently on dialysis
  • Subjects with severe comorbidities such as liver failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Endovascular Aneurysm Repair

Intervention Hierarchy (Ancestors)

Endovascular ProceduresVascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeBlood Vessel Prosthesis ImplantationVascular GraftingMinimally Invasive Surgical ProceduresProsthesis Implantation

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 7, 2025

First Posted

June 15, 2025

Study Start

June 1, 2025

Primary Completion

May 1, 2026

Study Completion (Estimated)

May 1, 2030

Last Updated

June 15, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share